Requip Articles
Variations in Parkinson's disease treatment among prescribers in France, Germany, Italy, Spain and the UK
2 December 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Drug candidates in pipeline offer potential for Parkinson's disease market, says Frost & Sullivan
9 December 2009
Azilect helps "double 2nd-line MAO-Bs in PD"
16 March 2009
Skyepharma further reduces loss in first half
8 September 2008
Stock Commentary - Europe - week to June 23, 2008
30 June 2008
Stock Commentary - Europe - week to June 16, 2008
23 June 2008
FDA approval for GSK
23 June 2008
GSK launches once-daily ReQuip XL in UK
19 May 2008
Final FDA approval of Mylan's generic Requip
12 May 2008
GSK sees 2008 EPS fall; posts 2007 results
18 February 2008
FDA extends decision date on Requip XL to 2nd-qtr 2008
11 February 2008
GSK's Requip Modutab approved in 8 EU countries
17 December 2007
Requip gets US FDA "approvable" letter
17 December 2007
Tentative FDA appro for Teva's Requip
10 December 2007
SkyePharma's 6-month loss reduced 11%
1 October 2007
FDA "approvable" for GSK's Requip CR
20 August 2007
Evidence of genetic link gives credibility to RLS
30 July 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
GSK/SkyePharma file Requip XL with US FDA
23 April 2007
GSK's Requip cuts off time in PD patients
16 April 2007
Stock Commentary - Europe - week to April 9
16 April 2007
No extra AEs for GSK's once-daily PD drug
11 September 2006
GSK's ReQuip fares well vs Schwarz' Neupro
17 April 2006
GSK EPS rises 10% on 6% sales growth
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
BI's pramipexole shows promise as RLS therapy
4 July 2005
GSK gets first appro for Requip for RLS in USA
16 May 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
SkyePharma sees net loss fall for 1st-half 2004, as sales rise and R&D costs decrease
20 September 2004
Stock Commentary - Europe
7 July 2003
SkyePharma starts Ph III trial for Requip OCR
7 July 2003
Requip shows use for restless legs syndrome
16 June 2003
Parkinson's drugs may slow progression
22 April 2002
UK MCA proposes POM-to-P switches
16 August 2001
Novartis/Orion seek entacapone use in early Parkinson's disease
18 October 2000
SB's ReQuip effective in restless leg syndrome
11 May 2000
SkyePharma outlines mission to become major player in drug delivery
23 February 2000
SB to issue physician's letter for ReQuip
16 February 2000
SB in new agreement with SkyePharma
15 September 1999
SB to purchase $10m stake in SkyePharma
5 August 1999
SB's Requip Effective Parkinson's Adjunct
29 October 1998
SmithKline Beecham's Requip Effective Parkinson's Adjunct
23 October 1998
Long-Term Efficacy With SB's Requip
15 May 1998
Requip May Preserve Function In Parkinson's
13 May 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
Massive Growth For Parkinson's Market
8 December 1997
SB's ReQuip Launched In USA
30 October 1997
Stock Comment Europe
2 October 1997
First COMT Inhibitor For Parkinson's Reaches Market
1 October 1997
SB's Requip Gets Approval In The USA
25 September 1997
SB's ReQuip Approved In Canada
4 September 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
Long-Term Data With SB's Ropinirole
22 April 1997
Entacapone And Tolcapone Near Market Introduction
26 March 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
SmithKline Beecham 3rd Qtr Earnings Leap 20%
28 October 1996
First Appro For SB's ReQuip Comes From The UK
15 July 1996
Ropinirole Relieves Parkinson's Symptoms
8 April 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
Showing 1-83 of 83 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
